President Trump’s executive order suspending federal funding for gain-of-function research not only contains questionable assertions, but it also frames the targeted research so broadly that it is likely to affect even lower-risk infectious disease research.
Related Posts
Innovations Driving Global and Regional Opportunities
The intersection of biotechnology and renewable energy is giving rise to an exciting new frontier: the solar-powered microbes market. By leveraging sunlight as an energy […]
A Guide for Healthcare Leaders
George McGregor, VP of Marketing for Approov Major cybersecurity breaches continue to plague the US healthcare industry, and on December 27, 2024, the U.S. Department […]
When the Doctor Needs a Checkup
Paula Span He was a surgical oncologist at a hospital in a Southern city, a 78-year-old whose colleagues had begun noticing troubling behavior in the […]